Figure 2

Low dose of CDV treatment does not impair the development of humoral immune response in surviving ECTV infected mice. Development of specific orthopoxvirus antibodies (IgG) in sera of CDV treated convalescent mice was determined by ELISA 30 days p.e.. Mice were infected intranasal with ECTV (35–60 pfu = 35–60 LD₅₀). Single CDV treatment with 2.5-100 mg/kg was given on the indicated days. Sera of infected, untreated mice were collected from convalescent mice that were infected with a low challenge dose (low CD, left bar, 0.1-1 pfu = 0.1-1 LD₅₀). Titer in GMT, error bars: Geometric standard deviation. Dotted line represents the average IgG titer of the 2.5-5 mg/kg versus 10–100 mg/kg treated groups. * Indicates for statistical significance (t-test, P < 0.01).